Collaboration with MANAT BIO, INC.

June 18, 2021 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with ManaT Bio on a series of quantitative proteomics focusing on leveraging Complete Omics clinical neoantigen detection and validation platforms, including MANA-SRM (basic research and tissue culture level) and Valid-NEO (clincial tumor tissue level) platforms.

ManaT Bio seeks to generate precision immunotherapies targeting the most ​common cancer-causing mutationsis, and it shares the same goal as Complete Omics Inc.  Complete Omics Inc is now empowering numerous cancer therapeutic companies by helping them accurately identify and quantify the neoantigens presented on the tumor cell surface.

Through the collaboration, we are aiming to use our MAMA-SRM developed in 2019 by our founder Dr. Qing Wang and our newly patented Valid-NEO technologies to empower ManaT Bio for their neoantigen-based personalized cancer therapeutic development.

Follow by Email